Merck licenses innovative anti-cancer therapy LM-299 from LaNova Medicines

In a strategic move to broaden its oncology portfolio, Merck & Co., Inc. (NYSE: MRK), recognized globally as MSD outside the U.S. and Canada, has ... Read More